ARIAD Announces Preliminary Data from Pivotal Pace Trial of Ponatinib, Its Investigational pan-BCR-ABL Inhibitor http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1638434&highlight= ARIAD will hold an investor meeting and webcast at 7:00 am (PST) on Monday, December 12, 2011 to review these data being presented at ASH.